Dr. Ola Landgren on Three-Drug Treatments and the Use of Monoclonal Antibodies
Ola Landgren, MD, PhD, on the progression treatments from combinations toward three-drug treatments and the use of monoclonal antibodies. Landgen adds that while he does have faith that monoclonal antibodies will change the treatment landscape in oncology, he says they could very well be combined with old and new drugs.
Ola Landgren, MD, PhD, head of the Myeloma Service, Memorial Sloan Kettering Cancer Center, professor of Medicine, Cornell Medical College, on the progression treatments from combinations toward three-drug treatments and the use of monoclonal antibodies. Landgen adds that while he does have faith that monoclonal antibodies will change the treatment landscape in oncology, he says they could very well be combined with old and new drugs.
Landgren says his hopes for three-drug treatments are mainly for the treatment of patients with "high risk" disease, he says they could also be useful in other risk types. Landgren cites the ASPIRE trial published in New England Journal Medicine, saying patients in the trial who received carfilzomib, lenalidomide, and dexamethasone gained an extra 10 months of progression-free survival.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
